Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 3
Submit an article Journal homepage
674
Views
21
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Luciano J. CostaDivision of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USACorrespondence[email protected]
,
Suzanne R. FanningGreenville Health System, Greenville, SC, USA
,
Joe Stephenson JrGreenville Health System, Greenville, SC, USA
,
Lawrence B. AfrinDivision of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
,
Emily Kistner-GriffinHollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
,
Tricia A. BentzHollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
&
Robert K. StuartDivision of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
 show all
Pages 645-649 | Received 07 Apr 2014, Accepted 08 Jun 2014, Published online: 17 Aug 2014

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Marc Sorigue, Elisa Orna & Juan-Manuel Sancho. (2018) Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review. Leukemia & Lymphoma 59:11, pages 2602-2611.
Read now
Francesca R. Mauro, Angelo M. Carella, Stefano Molica, Francesca Paoloni, Anna M. Liberati, Francesco Zaja, Valeria Belsito, Agostino Cortellezzi, Rita Rizzi, Patrizia Tosi, Mauro Spriano, Antonietta Ferretti, Mauro Nanni, Marilisa Marinelli, Maria S. De Propris, Sonia M. Orlando, Marco Vignetti, Antonio Cuneo, Anna R. Guarini & Robin Foà. (2017) Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial. Leukemia & Lymphoma 58:7, pages 1640-1647.
Read now
Abdallah Abou Zahr, Prithviraj Bose & Michael J. Keating. (2017) Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 18:9, pages 857-873.
Read now
Gilad Itchaki & Jennifer R. Brown. (2017) Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 26:5, pages 633-650.
Read now
Luca Laurenti, Idanna Innocenti, Francesco Autore, Simona Sica & Dimitar G Efremov. (2016) New developments in the management of chronic lymphocytic leukemia: role of ofatumumab. OncoTargets and Therapy 9, pages 421-429.
Read now
Punit L. Jain, Carrie Anne Orlikowski & Alessandra Ferrajoli. (2016) Lenalidomide in chronic lymphocytic leukemia. Expert Opinion on Orphan Drugs 4:9, pages 971-980.
Read now
Anna Maria Frustaci, Alessandra Tedeschi, Paola Picardi, Roberto Cairoli & Marco Montillo. (2015) Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia. Biologics: Targets and Therapy 9, pages 75-86.
Read now
Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2015) Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 20:3, pages 423-447.
Read now

Articles from other publishers (13)

Nikolaos Ioannou, Khushi Jain & Alan G. Ramsay. (2021) Immunomodulatory Drugs for the Treatment of B Cell Malignancies. International Journal of Molecular Sciences 22:16, pages 8572.
Crossref
Elisavet Vlachonikola, Kostas Stamatopoulos & Anastasia Chatzidimitriou. (2021) T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia. Cancers 13:13, pages 3255.
Crossref
Valentina Griggio, Francesca Perutelli, Chiara Salvetti, Elia Boccellato, Mario Boccadoro, Candida Vitale & Marta Coscia. (2020) Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Frontiers in Immunology 11.
Crossref
Rimda Wanchoo, Carolina Bernabe Ramirez, Jacqueline Barrientos & Kenar D Jhaveri. (2018) Renal involvement in chronic lymphocytic leukemia. Clinical Kidney Journal 11:5, pages 670-680.
Crossref
Bruce D. Cheson, Sari Heitner Enschede, Elisa Cerri, Monali Desai, Jalaja Potluri, Nicole Lamanna & Constantine Tam. (2017) Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. The Oncologist 22:11, pages 1283-1291.
Crossref
Kate Poropatich, Joel Fontanarosa, Sandeep Samant, Jeffrey A. Sosman & Bin Zhang. (2017) Cancer Immunotherapies: Are They as Effective in the Elderly?. Drugs & Aging 34:8, pages 567-581.
Crossref
Krzysztof Jamroziak, Bartosz Puła & Jan Walewski. (2017) Current Treatment of Chronic Lymphocytic Leukemia. Current Treatment Options in Oncology 18:1.
Crossref
Mizuki Nishino. (2016) Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment. Journal for ImmunoTherapy of Cancer 4:1.
Crossref
Liang Liang, Ming Zhao, Yuan-chao Zhu, Xin Hu, Li-ping Yang & Hui Liu. (2016) Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis. Annals of Hematology 95:9, pages 1473-1482.
Crossref
Nitin Jain & Susan O'Brien. (2016) Targeted therapies for CLL: Practical issues with the changing treatment paradigm. Blood Reviews 30:3, pages 233-244.
Crossref
Tadeusz Robak, Jerzy Z. Blonski & Pawel Robak. (2016) Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. Seminars in Oncology 43:2, pages 280-290.
Crossref
Kanti R. Rai & Preetesh Jain. (2016) Chronic lymphocytic leukemia (CLL)-Then and now. American Journal of Hematology 91:3, pages 330-340.
Crossref
Rossana Maffei, Elisabetta Colaci, Stefania Fiorcari, Silvia Martinelli, Leonardo Potenza, Mario Luppi & Roberto Marasca. (2016) Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology 97, pages 291-302.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.